Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4212MR)

This product GTTS-WQ4212MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4212MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13649MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ11558MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ5337MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ7159MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ6752MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ14265MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ13788MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ13901MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW